Command Palette

Search for a command to run...

Preprint WatchModerateAugust 26th, 2026

Chronic trazodone treatment consolidates sleep, improves memory, and reduces amyloid pathology in a mouse model of Alzheimer's disease

Arai, M.; Yue, J.; Shams, E.; Stevens, C. J.; Han, H.; Gibson, R.; Yildirim, T.; Feldman, H. H.; Wellington, C. L.; Kent, B. A.

Chronic trazodone administration consolidates slow wave sleep, improves memory and reduces amyloid pathology in an APP mouse model of Alzheimer's disease, positioning sleep architecture as a disease-modifying target upstream of amyloid.

Moderate contradiction

1 prior failure

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

The claim that reducing amyloid pathology in an APP mouse model translates into disease modification runs directly into the one APP failure on file. valiltramiprosate-alz801-app-apoe4-alzheimers-phase3-efficacy-failure recorded a Phase 3 efficacy failure of an anti-amyloid oral agent in the APOE4 homozygous population that was expected to respond most strongly, which is the archetype that triggers a MODERATE flag. The preprint's mechanism is indirect, acting through sleep rather than through amyloid binding, so it is not refuted by that trial. What the prior failure does establish is that amyloid burden reduction in a model system is a weak predictor of cognitive benefit in patients, and any clinical plan built on this preprint should carry a cognitive endpoint rather than an amyloid endpoint as its primary test.

Abstract excerpt

Sleep disturbance in Alzheimer's disease (AD), particularly the reduction of slow wave sleep (SWS), has been proposed as a novel therapeutic target, with disease-modifying potential. Trazodone, an antidepressant with robust SWS-promoting properties, is currently the most prescribed sleep-promoting medication in the United States. Here, we demonstrate that chronic trazodone administration consolidates sleep in the APP NL-F knock-in mouse model of AD, increasing NREM sleep duration and slow wave power during the rest phase while promoting wake during the active phase. These sleep consolidating effects were accompanied by lower regional glial activation and amyloid burden, particularly in male mice. Most notably, hippocampal amyloid plaque burden was 45% lower in mice treated from 14 to 16 months of age than in vehicle-treated controls. Chronic trazodone treatment was also associated with better short-term and long-term recognition memory. Together, these findings support the potential of repurposing trazodone as a well-tolerated, disease-modifying therapeutic for AD, capable of enhancing sleep quality, improving cognition, and lowering AD-relevant neuropathology.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.